Clinical and Preclinical Results for Acetylon Pharmaceuticals' ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today presented clinical and preclinical results for its selective histone deacetylase (HDAC) 6 inhibitor, ACY-1215, for the treatment of multiple myeloma (MM) at the 54th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, Georgia. Preliminary results from the Phase 1/2 study of ACY-1215 suggest that selective inhibition of HDAC6 with ACY-1215 in combination with bortezomib (VelcadeĀ®, Takeda Millennium Pharmaceuticals) and dexamethasone may provide a well-tolerated treatment option for relapsed or relapsed/refractory MM. In addition, preclinical results for ACY-1215 indicate a potential beneficial role of HDAC6 inhibition in MM-related bone disease. Together, these results show that selective HDAC6 inhibition through ACY-1215 may act favorably on both tumors and bone forming cells to benefit patients with MM.

Back to news